Creative Biolabs, a global contract research organization, has launched an end-to-end antisense oligonucleotide (ASO) development service designed to address technical challenges that often slow the translation of RNA therapeutics from concept to clinic. The platform integrates proprietary bioinformatics, chemical synthesis, delivery technologies, and preclinical validation under a single pipeline, aiming to reduce timelines and improve data consistency for researchers.
ASO therapeutics have emerged as a powerful modality for targeting diseases at the genetic level, but their development is frequently hindered by issues such as off-target effects, enzymatic degradation, and inefficient delivery to specific tissues. Traditionally, researchers have had to coordinate with multiple vendors for different stages of development, leading to fragmented workflows and potential data inconsistencies. Creative Biolabs' new service unifies these steps, offering a streamlined process from design through preclinical testing.
Key components of the platform include proprietary bioinformatic tools that use thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions, reducing off-target risks. The synthesis capabilities cover a range of oligonucleotide architectures, including Gapmers and steric-blocking oligos, with scales from milligram to multi-gram. Chemical modifications such as phosphorothioate (PS) backbones, phosphorodiamidate morpholino oligomers (PMO), and sugar modifications like 2'-MOE and cEt are employed to enhance nuclease resistance and in vivo stability.
Delivery remains a critical hurdle for ASO therapeutics. Creative Biolabs addresses this through custom conjugation technologies, including GalNAc conjugation for liver targeting, antibody-oligonucleotide conjugates (AOCs) for extrahepatic tissues, and specialized lipid nanoparticle (LNP) formulations. These approaches aim to improve cellular uptake and tissue specificity, potentially lowering required doses and improving safety profiles.
Preclinical validation services include in vitro screening for mRNA knockdown via qPCR and cytotoxicity testing, as well as in vivo pharmacokinetic/pharmacodynamic profiling. These data-rich assessments support candidate selection and further development planning.
"Many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability," stated the Chief Scientific Officer at Creative Biolabs. "Our one-stop platform eliminates these silos. By matching customized chemical modifications with precise conjugation chemistries early in the design phase, we significantly lower required doses and improve the safety profiles of our clients' candidates."
The company's portfolio includes ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases. For more information, visit Creative Biolabs Gene Therapy.
